Premium
P2‐409: Results of a two‐step crossover study of donepezil (Aricept) to rivastigmine patch (Exelon Patch) in Alzheimer's disease patients: A two‐month clinical experience
Author(s) -
Shua-Haim Joshua,
Yap Celeste,
Kretov Aleksey,
Lee Paul
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1488
Subject(s) - donepezil , rivastigmine , tolerability , medicine , adverse effect , dementia , morning , anesthesia , disease
day. No AE was reported with rivastigmine treatment at 4.6mg /day dosing. At 9.5mg/day dosing, the reported AE were tiredness / sleepiness in 18 (15.5%) patients and skin rash in 3 (2.5%) patient. Noticeable cognitive deterioration was reported by caregivers in 66 (22.4%) patients during the first month of treatment. All such patients were treated with donepezil 10mg/day before switch. Conclusions: Next day crossover from donepezil (Aricept) to rivastigmine (Exelon) patch was well tolerated. A noticeable cognitive deterioration was reported by caregivers in 22% of patients whose treatment was switched from donepezil 10mg/day to rivastigmine patch 4.6mg/day.